Appendix C
HIV Background Tables
This appendix includes information about HIV/AIDS to support discussion in Chapter 2. Table C-1 lists the AIDS-defining illnesses as determined by the Centers for Disease Control and Prevention, as well as a noninclusive list of contemporary, serious non-AIDS-defining illnesses. Table C-2 provides a nonexhaustive list of HIV/AIDS antiretroviral drugs and their potential side effects.
TABLE C-1 HIV/AIDS-Related Illnesses and Malignancies
AIDS-Defining Illnessesa |
Serious Non-AIDS-Defining Illnessesb |
|
|
aCDC AIDS-defining illnesses (CDC, 1994). |
TABLE C-2 Current HIV/AIDS Antiretroviral Drugs
Generic Name |
Brand Name |
Approval Date |
Potential Side Effects |
Multiclass Combination Products |
|||
Efavirenz, emtricitabine, and tenofovir disoproxil fumarate |
Atripla |
July 12, 2006 |
|
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) |
|||
Abacavir and lamivudine |
Epzicom |
August 2, 2004 |
|
Abacavir, zidovudine, and lamivudine |
Trizivir |
November 14, 2000 |
|
Abacavir sulfate, ABC |
Ziagen |
December 17, 1998 |
|
Didanosine, dideoxyinosine, ddI |
Videx |
October 9, 1991 |
|
Emtricitabine, FTC |
Emtriva |
July 2, 2003 |
|
Enteric-coated didanosine, ddI EC |
Videx EC |
October 31, 2000 |
|
Generic Name |
Brand Name |
Approval Date |
Potential Side Effects |
Lamivudine and zidovudine |
Combivir |
September 27, 1997 |
|
Lamivudine, 3TC |
Epivir |
November 17, 1995 |
|
Stavudine, d4T |
Zerit |
June 24, 1994 |
|
Tenofovir disoproxil fumarate and emtricitabine |
Truvada |
August 2, 2004 |
|
Tenofovir disoproxil fumarate, TDF |
Viread |
October 26, 2001 |
|
Zalcitabine, dideoxycytidine, ddC (no longer marketed) |
Hivid |
June 19, 1992 |
|
Zidovudine, azidothymidine, AZT, ZDV |
Retrovir |
March 19, 1987 |
|
Generic Name |
Brand Name |
Approval Date |
Potential Side Effects |
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) |
|||
Delavirdine, DLV |
Rescriptor |
April 4, 1997 |
|
Efavirenz, EFV |
Sustiva |
September 17, 1998 |
|
Etravirine |
Intelence |
January 18, 2008 |
|
Nevirapine, NVP |
Viramune |
June 27, 1996 |
|
Protease Inhibitors (PIs) |
|||
Amprenavir, APV |
Agenerase |
April 15, 1999 |
|
Atazanavir sulfate, ATV |
Reyataz |
June 20, 2003 |
|
Darunavir |
Prezista |
June 23, 2006 |
|
Fosamprenavir calcium, FOS-APV |
Lexiva |
October 20, 2003 |
|
Indinavir, IDV |
Crixivan |
March 13, 1996 |
|
Lopinavir and ritonavir, LPV/RTV |
Kaletra |
September 15, 2000 |
|
Nelfinavir mesylate, NFV |
Viracept |
March 14, 1997 |
|
Ritonavir, RTV |
Norvir |
March 1, 1996 |
|
Saquinavir (no longer marketed) |
Fortovase |
November 7, 1997 |
|
Saquinavir mesylate, SQV |
Invirase |
December 6, 1995 |
|
Tipranavir, TPV |
Aptivus |
June 22, 2005 |
|
Generic Name |
Brand Name |
Approval Date |
Potential Side Effects |
Fusion Inhibitors |
|||
Enfuvirtide, T-20 |
Fuzeon |
March 13, 2003 |
|
Entry Inhibitors—CCR5 Coreceptor Antagonist |
|||
Maraviroc |
Selzentry |
August 6, 2007 |
|
HIV Integrase Strand Transfer Inhibitors |
|||
Raltegravir |
Isentress |
October 12, 2007 |
|
REFERENCE
CDC (Centers for Disease Control and Prevention). 1994. Revised classification system for HIV-infection in children less than 13 years of age. Morbidity and Mortality Weekly Report 43:1–10.